Backgrounds/Aims: Hilar cholangiocarcinomas (HLC) are known to have worse prognoses than mid-to-distal cholangiocarcinomas (CBDC). We analyzed the clinical results of surgical resections for extrahepatic cholangiocarcinomas to validate the differences in the prognoses of HLC and CBDC. Methods: Two hundred and eighty-one patients underwent curative surgical resections for extrahepatic cholangiocarcinomas at the Department of Surgery in the Korea Cancer Center Hospital. Among them, we analyzed the T2 and T3 patients and compared the clinical results between those with HLC (n=74) and those with CBDC (n=65). Results: The rate of R1 resections was significantly higher in the HLC patients compared to the CBDC patients (31.1% vs 12.3%, p=0.006). The overall survival rate of the T2/T3 patients was lower in the HLC group than in the CBDC group (24.5% vs 51.7, p=0.039). The recurrence-free survival rate was 23.3% in the HCL patients and 50.9% in the CBDC patients (p=0.06). In the subgroup analysis, the survival rates were not different in patients who had lymph node metastases or in patients who underwent R1 resections between the HLC and CBDC patients. Poor independent prognostic factors for the overall and recurrence-free survival rates in the T2/T3 extrahepatic cholangiocarcinoma patients were the presence of lymph node metastases and the hilar locations of tumor. Conclusions: HLC patients had poorer prognoses than CBDC patients. However, in patients with lymph node metastases, the prognosis was poor and was not different between the HLC and CBDC patients. Other adjuvant treatment methods are needed for extrahepatic cholangiocarcinoma patients with lymph node metastases to improve their prognoses. (Ann Hepatobiliary Pancreat Surg 2019;23:319-326)
INTRODUCTION
Cholangiocarcinomas account for approximately 3% of all gastrointestinal malignancies, with a prevalence in autopsy studies of 0.01 to 0.46 percent. In the United States, the incidence of bile duct cancer is between one and two patients per 100,000 people and 3,500 cases occur every year. 1 However, South Korea has been reported to be one of the countries with a high incidence of bile duct cancer. 2 Of the 214,701 newly-registered cancer patients in 2015, patients with extrahepatic bile duct cancer ranked ninth and had the sixth highest mortality rate in South Korea. 3 Cholangiocarcinomas can be classified into intrahepatic cholangiocarcinomas and extrahepatic cholangiocarcinomas according to their location. Extrahepatic cholangiocarcinoma can be further classified into hilar cholangiocarcinomas (HLC), mid-bile duct cancer, and distal bile duct cancer (CBDC). 4, 5 Hilar cholangiocarcinoma (HLC) involves the common hepatic duct and the confluence of the left and right hepatic duct and accounts for 60-70% of all extrahepatic cholangiocarcinomas. 6 Middle-to-distal cholangiocarcinomas (CBDC) account for 20-40% of the extrahepatic cholangiocarcinomas. 7 The primary treatment for cholangiocarcinoma is surgical treatment but it has been reported that only 10 to 40% of patients with cholangiocarcinomas could be resected. 8 Curative surgery for cholangiocarcinoma depends on the site of tumor development. Pancreaticoduodenectomy is have reported that the prognosis for HLC was worse than that for CBDC. 9, 10 The possible cause of the difference is that symptoms, such as jaundice and cholangitis, develop more quickly, so can be diagnosed quickly in CBDC.
The relatively higher resection rate in CBDC is due to the lower incidence of liver and major vessel invasions compared to HLC. 11 The purpose of this study was to compare the prognosis of HLC and CBDC after curative resections in our hospital. The difference between the 5-year overall survival rates were statistically significant (p=0.039) ( Fig. 1) . In the T2 patients, the 5-year overall survival rate of patients with HLC was not different from that of the CBDC patients.
MATERIALS AND METHODS

Patient and data collection
In contrast, in the T3 patients, the 5-year survival rate of the HLC patients was 15.5% and that of the CBDC patients was 59.5 percent. The difference was statistically significant (p=0.043) (Fig. 2) . The 5-year overall survival rate of HLC in N0 patients was 28.6% and that of the CBDC patients was 70.0 percent. The rates were statistically significant (p=0.001). In the N1 patients, the 5-year overall survival rate in patients with HLC was 14.1% and was not statistically different from CBDC, which was 29.3 percent ( Fig. 3 ).
In the R0 resection patients, the 5-year overall survival rate of patients with HLC was 19.8% and that of CBDC was 55.5%, which was significantly different (p=0.019).
The 5-year overall survival rates of HLC and CBDC were not statistically different in patients with R1 resections Fig. 3 . Comparison of the overall-survival rates between hilar cholangiocarcinoma and distal bile duct cancer according to N stages.
Fig. 5.
Comparison of the recurrence-free survival rates between hilar cholangiocarcinoma and distal bile duct cancer according to cancer location (T2/T3).
Fig. 4.
Comparison of the overall-survival rates between hilar cholangiocarcinoma and distal bile duct cancer according to R0/R1 resections.
( Fig. 4) .
The 5-year recurrence-free survival rate of HLC was 23.3% and this was lower than that of the CBDC patients, but this difference was not statistically significant (p= 0.06) (Fig. 5 ). . 7 . Comparison of the recurrence-free survival rates between hilar cholangiocarcinoma and distal bile duct cancer according to N stages. Fig. 8 . Comparison of the recurrence-free survival rates between hilar cholangiocarcinoma and distal bile duct cancer according to R0/R1 resections. (Fig. 7) .
In the R0 resection patients, the 5-year recurrence-free survival rate of the HLC patients was 21.5% and that of the CBDC patients was 50.8%, which was statistically significant (p=0.039). The 5-year recurrence-free survival rates of R0 patients in the HLC and CBDC groups were not significantly different (Fig. 8 ).
Multivariate analysis revealed that lymph node metastases and hilar tumor locations were independent poor prognostic factors for both the overall and recurrence-free survival rates in these patients ( Table 2 ).
DISCUSSION
Occasionally, extrahepatic bile duct cancer is found at an advanced stage. 12, 13 tumor differentiation status and blood transfusions. 15, 16 The results of adjuvant treatment for extrahepatic bile duct cancer, such as chemotherapy and radiotherapy, are not satisfactory. 17 But a few recent studies showed a slight survival gain. 18 Gabriel et al. 19 reported that gemcitabine plus cisplatin for biliary cancer provided survival benefit.
Moureau-Zabotto et al. reported that the conformal-3D external-beam-radiotherapy (EBRT) seemed efficient to treat locally-advanced and unresectable extrahepatic cholangio-carcinomas, with acceptable toxicity. 20 Many studies have demonstrated that the prognosis for HLC was worse than that for CBDC. 21, 22 Park et al. 23 reported that the 5-year survival rate of patients with extrahepatic cholangiocarcinoma, on the site of the tumor, were higher in CBDC. The histologic structure of the extrahepatic bile duct can be different depending on its location. In the hilar area, the muscle fiber is scattered. But the distal bile duct consists of smooth muscle bundles.
Although differences in the degree of tumor invasion have been investigated, the fibromuscular, subserosa, and serosa layers are very thin histologically, therefore, it is difficult to distinguish the infiltration limit between them. 24 Differences in local invasion or lymph node metastases due to these anatomical and histologic differences may lead to differences in survival rates but currently, there is no definitive consensus in the literature. Baek et al. reported that there was no difference in prognosis related to the location of bile duct cancer and that R0 resection was the most important factor affecting prognosis. 25 In our study, a total of 281 patients underwent surgery for extrahepatic cholangiocarcinomas. However, the number of patients with T1 was small and curative resections frequently could not be performed in the patients with T4.
Therefore, we selected patients with only T2 and T3 stage cancers who underwent successful resection for our study.
In this study, a hilar location of the cholangiocarcinoma was an independent poor prognostic factor.
In R0 resected patients with HLC, the prognosis was poorer than for those with CBDC. In R1 resected patients, 5-year survival rate in patients with lymph node metastases. 26 Yoshida et al. 27 also reported that lymph node stage was an independent prognostic factor. Patients with up to two positive lymph nodes had a more favorable prognosis than that of other patients. The authors recommended pancreaticoduodenectomies with extended lymphadenectomies and adjuvant chemotherapy for the treatment of patients with CBDC. Kitagawa et al. 28 analyzed the patterns of lymph node metastases of HLC and emphasized that aggressive lymphadenectomy was necessary because the pericholedocal node was the most common site of lymph node metastasis and that metastasis occurred along the lymphatic drainage system. Patients with lymph node metastases also had significantly lower overall survivals and recurrence-free survivals in this study.
This study revealed that the prognosis for HLC patients was worse than for CBDC patients under curative surgical conditions. However, in cases of lymph node metastases or R1 resections, the prognosis was poor and not different between patients with HLC or CBDC.
In conclusion, we should do our best to perform R0 resections to achieve better prognoses. The development of new adjuvant treatment methods for extrahepatic bile duct cancers with lymph node metastases is necessary. Further studies into the cause of the differences in survival rates between HLC and CBDC patients are needed.
